For drug registration in Taiwan, clinical trials must demonstrate the drug’s safety, efficacy, and quality. These typically include Phase I trials for safety, Phase II for efficacy, and Phase III for large-scale testing. Bridging studies may also be required to confirm the... Read More
The drug registration process in Taiwan typically takes 12 to 18 months for standard applications, depending on the completeness of the submission and drug type. Priority or orphan drugs may undergo accelerated review, reducing approval times, while generics can be approved within... Read More
In Taiwan’s drug registration, **New Chemical Entities (NCEs)** are innovative drugs with new active ingredients not previously approved, requiring extensive clinical trials and a thorough TFDA review. **Generics**, by contrast, replicate existing drugs, needing only bioequivalence studies to demonstrate similar efficacy and... Read More
In Taiwan, biologics are registered through the Taiwan FDA (TFDA) with a process similar to that for chemical drugs but requiring more detailed clinical, manufacturing, and quality data. Submissions must include evidence of Good Manufacturing Practices (GMP) compliance, stability studies, and immunogenicity... Read More
In Taiwan’s drug registration process, **New Chemical Entities (NCEs)** are innovative drugs containing active ingredients that have not been previously approved or marketed domestically. These drugs undergo rigorous evaluation for safety, efficacy, and quality through preclinical and clinical trials, with TFDA offering... Read More
A New Drug Application (NDA) in Taiwan requires clinical trial results, quality control data, manufacturing details, pharmacological data, and Good Manufacturing Practices (GMP) compliance documentation. Additional materials include a product summary, labeling information, and translated documents if necessary. Submissions must be made... Read More
To submit a New Drug Application (NDA) in Taiwan, you must provide clinical trial data, quality assessments, and manufacturing information through the Taiwan FDA’s (TFDA) e-submission platform. The application must comply with Good Manufacturing Practices (GMP) and may require translation into Chinese.... Read More
The Pharmaceutical Affairs Act in Taiwan establishes the legal framework for regulating drugs and medical products, ensuring their safety, efficacy, and quality. It covers the approval process, manufacturing standards, import/export regulations, and post-market surveillance. The act also mandates Good Manufacturing Practices (GMP)... Read More
Drug registration in Taiwan is governed by the Pharmaceutical Affairs Act, which sets standards for safety, efficacy, and quality. The Controlled Drugs Act and Taiwan FDA (TFDA) guidelines further regulate Good Manufacturing Practices (GMP), clinical trials, and post-market surveillance, ensuring compliance throughout... Read More
The Taiwan Food and Drug Administration (TFDA) manages drug registration by overseeing submissions, conducting reviews, ensuring GMP compliance, and performing post-market monitoring. It offers expedited pathways for priority drugs and supports e-submissions to streamline processes, ensuring drug safety, efficacy, and quality throughout... Read More